Doximity Stock Slides 22.5% on Q4 Revenue Miss, Revised Outlook
1h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
doximityhealthcare-technology
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
Shares of Doximity, Inc. (NYSE: DOCS) declined sharply on June 29, 2026, following the company's release of its fiscal fourth-quarter and full-year 2026 financial results. The digital platform for medical professionals reported quarterly revenue of $118.3 million, falling short of the consensus analyst estimate of $121.5 million. Investing.com first reported the stock's slide, which saw shares trade down approximately 22.5% in the pre-market session. The company also issued guidance for fiscal 2027 that fell below Wall Street's prior expectations, triggering a significant reassessment of its near-term growth trajectory.
The sell-off marks one of Doximity's most severe single-day declines since its initial public offering in 2021. In February 2025, the stock fell 19% after issuing guidance that signaled a slowdown in its core pharmaceutical marketing business. The current macro backdrop for healthcare technology remains challenging, with the Nasdaq Composite's healthcare index down 4% year-to-date as of June 28, 2026, pressured by higher interest rates and tighter hospital capital budgets.
The immediate catalyst for the decline was the dual disappointment of a Q4 revenue miss and softer-than-anticipated forward guidance. Doximity's revenue grew 10% year-over-year in Q4, a deceleration from the 17% growth posted in the previous quarter. Management cited elongated sales cycles for its newer enterprise solutions and a more cautious spending environment among life sciences clients as primary factors. This triggered concerns that the company's flagship business, which generates most of its revenue from pharmaceutical marketing, is maturing faster than its newer product lines can scale.
Doximity's fiscal Q4 2026 revenue of $118.3 million missed the $121.5 million consensus estimate. Adjusted earnings per share for the quarter were $0.22, which aligned with forecasts. For the full fiscal year 2026, revenue was $464.7 million, representing 13% year-over-year growth. This growth rate has slowed sequentially from 21% in fiscal 2025 and 58% in fiscal 2024.
The company's guidance for fiscal 2027 projects revenue between $500 million and $510 million, implying a growth rate of 7.6% to 9.7% at the midpoint. This is materially below the previous analyst consensus of approximately $530 million. The stock's decline of 22.5% reduced its market capitalization by roughly $2.1 billion in pre-market trading. In comparison, the iShares U.S. Healthcare ETF (IYH) was flat in early trading, and peer Teladoc Health (TDOC) was down 1.5%.
| Metric | Q4 FY2026 Actual | Consensus Estimate | Variance |
|---|---|---|---|
| Revenue | $118.3M | $121.5M | -2.6% |
| Adjusted EPS | $0.22 | $0.22 | 0.0% |
| FY2027 Revenue Guide (Midpoint) | $505M | ~$530M | -4.7% |
The reaction highlights the market's low tolerance for growth deceleration in software-as-a-service stocks, particularly those trading at premium valuations. Doximity entered the report trading at approximately 35 times forward earnings, a multiple that has now contracted sharply. The sell-off creates a negative read-across for other digital health and healthcare IT companies reliant on pharmaceutical advertising budgets, such as Veeva Systems (VEEV) and Health Catalyst (HCAT).
A key limitation to the bearish thesis is Doximity's continued profitability and strong net income retention rate of over 110%, indicating existing customers are spending more. The company's balance sheet remains strong with over $800 million in cash and no debt. Despite this, positioning data and flow analysis suggest institutional investors are likely reducing exposure. Options flow showed a surge in put volume at the $27.50 strike price, indicating hedging or directional bets on further downside.
Investors will monitor Doximity's next earnings report, scheduled for late September 2026, for signs of stabilization in the sales pipeline. Key levels to watch on the chart include the stock's 2025 low of $24.50, which now serves as critical support. Resistance is likely to form near the $30 level, where the stock gapped down at the open.
The broader catalyst for the sector will be the quarterly earnings of major pharmaceutical firms like Pfizer (PFE) and Merck (MRK) in late July, which provide signals on overall drug marketing expenditure. If Doximity's management can demonstrate sequential improvement in revenue growth in the next quarter, particularly from its newer Nexus platform for hospitals, sentiment could stabilize. Until then, the stock is likely to remain under pressure.
The sell-off challenges the thesis that Doximity can seamlessly transition from a medical network into a broad healthcare workflow platform without a growth hiccup. The company's high profitability and cash generation remain intact, but the market is now demanding proof that its newer hospital and telehealth products can achieve similar scale to its legacy pharma business. Long-term success hinges on cross-selling these solutions to its existing, highly engaged physician user base.
Teladoc's 2022 decline was driven by massive goodwill impairments and concerns over the sustainability of its chronic care business after the Livongo acquisition. Doximity's issue is different; it is a pure execution miss on growth expectations, not a fundamental impairment of its assets. Doximity also maintains a much stronger balance sheet and has never reported an annual net loss, unlike Teladoc during its growth investment phase.
Before this report, Doximity traded at a forward P/E of around 35, a premium to the healthcare technology sector average of approximately 25. This premium was justified by its high net margins (over 30%) and consistent profitability in a sector known for losses. The post-earnings multiple compression brings it closer to sector peers, but it may still command a slight premium if growth re-accelerates to low double-digits, as seen with other best-in-class SaaS companies like Salesforce in past cycles.
Doximity's growth deceleration has reset investor expectations, shifting the stock from a premium-priced growth story to a show-me narrative focused on execution.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.